Cosmos Health Inc.: Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform - Record Growth with U.S. Expansion Underway
Cosmos Health CEO Greg Siokas told shareholders the company hit record results, including FY2025 revenue of $65.3M (up 20% YoY) and the highest Q1 2026, with momentum into Q2. The firm cited record volumes in CosmoFarm wholesale and GMP-certified Cana contract manufacturing, and U.S. entry generating revenue. Cosmos targets by 2029: $200M+ revenue, $44.2M Adjusted EBITDA, and $92.3M stockholders’ equity, and is pursuing up to €25M financing with the EIB.
The article is a management update combining new performance claims, margin trajectory, and multi-year financial targets, plus a stated EIB financing pursuit.
Cosmos Health CEO letter cites record FY2025 revenue ($65.3M), Q1 2026 strength, and 2029 targets ($200M+ revenue, $44.2M Adj. EBITDA).
Near-term sentiment could improve if investors view the 2029 targets and U.S. revenue ramp as credible; however, the CEO also notes the stock has declined, implying skepticism risk.
Background
The piece is a CEO shareholder letter updating Cosmos Health’s progress since September 2025, framing the company as an AI-driven, vertically integrated global healthcare platform.
Why it matters
The letter provides new quantitative milestones (record FY2025 revenue, strongest-ever Q1 2026, gross margin trajectory) and multi-year guidance to 2029, plus a stated financing pursuit with the European Investment Bank and claims of active U.S. revenue generation.
Market relevance
For traders, the actionable items are the specific 2029 financial targets, the claimed U.S. revenue generation with ~75% gross margins, and the stated EIB financing pursuit—each can influence valuation expectations and near-term sentiment.
Market effects
If believed, the vertical-integration + AI-driven platform narrative could strengthen investor appetite for small/mid-cap healthcare roll-ups and AI-enabled drug discovery/repurposing stories.
U.S. market entry “active and generating revenue” may shift attention toward North America execution risk and distribution/manufacturing capacity for similar operators.
EIB financing pursuit (up to €25M) highlights European development-capital channels that could matter for other EU-linked biotech/healthcare platforms.
Alternative perspectives
Targets and margin expansion projections may be viewed as aspirational without independent confirmation; the CEO’s admission that the stock declined suggests the market may already discount parts of the story.
Key execution risks remain around the timing of U.S. revenue ramp, gross margin sustainability, and whether the EIB financing program is finalized on favorable terms.
Key entities
- companyCosmos Health Inc.
NASDAQ-listed diversified healthcare platform; CEO letter highlights record revenue, margin expansion path, U.S. entry revenue, and 2029 targets.
- lender/regulatorEuropean Investment Bank
Company states it is pursuing an EIB financing program of up to €25M.
- platformCloudscreen
AI-driven drug repurposing platform referenced as supporting the R&D pipeline.
